CTOs on the Move

Essia Health

www.essiahealth.com

 
Our story begins in 2005, with a healthcare professional, Dr. Kathleen Myers. She was hired to help open a new, paperless hospital using multiple EMRs and CPOE. A dedicated emergency medicine physician, she knew that every minute counted and worried that “going paperless” would take valuable time away from patients — which was unacceptable. She challenged herself to find a solution. Her answer was a scribe program. She championed development of this for her emergency department, and scribes quickly became an indispensable part of her practice of medicine. So much so, that Dr. Myers sought the support of like-minded individuals with ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Accent Urgent Care and After Hours Pediatrics

Accent Urgent Care and After Hours Pediatrics is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deerwalk

Deerwalk Incorporated is a revolutionary Population Health Management and Healthcare Analytics Software Company, which offers customers a range of quality products and services to meet their healthcare needs. Deerwalk`s understanding and experience in the Healthcare Analytics industry is unparalleled, offering Big Data and NoSQL products and services to Third Party Administrators, Brokers and Consultants, Employers and Providers, Health Plans, Accountable Care Organizations, Disease / Care Managers, and Health Coaches.

DiagnosisONE Inc.

DiagnosisONE Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Cirtec Medical Systems

Cirtec Medical Systems is a Los Gatos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.